• LAST PRICE
    21.4600
  • TODAY'S CHANGE (%)
    Trending Down-0.9600 (-4.2819%)
  • Bid / Lots
    21.0000/ 1
  • Ask / Lots
    25.0000/ 1
  • Open / Previous Close
    22.5700 / 22.4200
  • Day Range
    Low 21.3000
    High 23.2832
  • 52 Week Range
    Low 20.0100
    High 37.8200
  • Volume
    153,808
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 22.42
TimeVolumeADCT
09:32 ET99323.2832
09:35 ET40022.53
09:37 ET10022.51
09:39 ET76622.3
09:42 ET220022.21
09:44 ET100022.365
09:46 ET39522.1
09:48 ET30522.1
09:51 ET10021.95
09:55 ET70021.66
09:57 ET159321.8
10:00 ET15021.94
10:04 ET30021.61
10:06 ET80021.755
10:09 ET40421.735
10:18 ET105521.85
10:20 ET10021.85
10:22 ET20021.99
10:26 ET10022.005
10:27 ET216921.91
10:29 ET50021.9
10:31 ET40021.75
10:33 ET10021.755
10:36 ET180021.76
10:38 ET64221.75
10:40 ET10021.735
10:42 ET30021.73
10:45 ET10021.66
10:47 ET52221.66
10:49 ET49421.75
10:54 ET20021.66
10:56 ET30021.75
10:58 ET20021.75
11:00 ET30021.71
11:02 ET150021.75
11:05 ET101621.75
11:07 ET10021.675
11:12 ET48421.71
11:16 ET80021.71
11:18 ET90121.66
11:21 ET71221.74
11:27 ET60321.875
11:41 ET90021.83
11:43 ET10021.8475
11:45 ET200021.83
11:52 ET30021.82
11:54 ET30021.79
11:56 ET10021.785
12:01 ET50021.69
12:08 ET100021.71
12:10 ET10021.74
12:14 ET20021.74
12:15 ET70021.705
12:17 ET53821.77
12:19 ET73521.84
12:24 ET30021.78
12:28 ET369421.85
12:30 ET10021.73
12:32 ET10021.73
12:33 ET50021.73
12:39 ET15021.8183
12:42 ET382721.85
12:44 ET90021.91
12:46 ET188621.88
12:50 ET140021.845
12:51 ET10021.78
12:55 ET60021.79
01:00 ET10021.76
01:02 ET10021.751
01:04 ET10021.75
01:08 ET273221.7825
01:11 ET20021.885
01:18 ET30021.895
01:20 ET20021.84
01:22 ET10021.875
01:26 ET50021.8
01:27 ET10021.75
01:33 ET160021.58
01:40 ET150021.72
01:42 ET20721.73
01:44 ET60021.65
01:47 ET262321.74
01:49 ET30021.63
01:51 ET40021.75
01:54 ET492521.785
01:56 ET20021.785
02:00 ET73021.76
02:05 ET60021.765
02:14 ET70021.66
02:18 ET587121.61
02:20 ET103621.63
02:21 ET242021.555
02:23 ET163021.595
02:25 ET30021.58
02:27 ET10021.58
02:30 ET11521.5779
02:32 ET80021.555
02:34 ET290021.69
02:36 ET20021.7
02:45 ET200521.635
02:48 ET227421.795
02:50 ET120021.7
02:52 ET70021.7
02:54 ET310021.72
02:56 ET220021.78
02:57 ET130021.8
03:01 ET10021.89
03:03 ET84121.55
03:06 ET10021.55
03:08 ET10021.54
03:10 ET29021.6011
03:15 ET112521.675
03:19 ET30021.57
03:21 ET20021.7
03:30 ET20021.585
03:32 ET30021.59
03:33 ET10021.58
03:37 ET396021.715
03:39 ET20021.61
03:42 ET140021.58
03:44 ET10021.59
03:46 ET676021.535
03:48 ET82421.465
03:50 ET50021.41
03:51 ET142721.38
03:53 ET334921.49
03:55 ET70021.465
03:57 ET166021.48
04:00 ET546421.46
Data delayed at least 15 minutes.

Nov 9, 2021

Nov 4, 2021

0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesADCT
ADC Therapeutics SA
1.6B
-6.5x
---
United StatesISEE
Iveric Bio Inc
1.6B
-12.6x
---
United StatesATAI
ATAI Life Sciences NV
1.7B
0.0x
---
United StatesKRYS
Krystal Biotech Inc
1.7B
-25.1x
---
United StatesCLDX
Celldex Therapeutics Inc
1.7B
-20.3x
---
United StatesERAS
Erasca Inc
1.7B
0.0x
---
As of 2021-12-04

Company Information

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Contact Information

Headquarters
Biopole, route de la Corniche 3BEPALINGES, Switzerland 1066
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Ron Squarer
Chief Executive Officer, Executive Director
Christopher Martin
Vice Chairman of the Board, Executive Vice President, General Counsel
Michael Forer
Chief Financial Officer
Jennifer Creel
Senior Vice President, Chief Human Resource Officer
Kimberly Pope

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.6B
Revenue (TTM)
$16.9M
Shares Outstanding
76.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.28
Book Value
$4.37
P/E Ratio
-6.5x
Price/Sales (TTM)
97.4
Price/Cash Flow (TTM)
---
Operating Margin
-1,638.02%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.